Literature DB >> 28274512

Practical use and utility of fluorescence in situ hybridization in the pathological diagnosis of soft tissue and bone tumors.

Shintaro Sugita1, Tadashi Hasegawa2.   

Abstract

During routine pathological examination, fluorescence in situ hybridization (FISH) plays a significant role in the genetic analysis of samples. FISH can detect genetic abnormalities such as chromosomal translocations, gene amplifications, and deletions in formalin-fixed, paraffin-embedded (FFPE) specimens. Due to its practical advantages, FISH is already used in many pathology laboratories. It is especially useful for the diagnosis of translocation-related sarcomas (TRSs), which comprise about 25% of soft tissue sarcomas. Because TRSs have specific chimeric genes derived from characteristic chromosomal translocations, their diagnosis would not be possible without FISH. FISH significantly contributes to the genetic confirmation of TRS. Analysis using next-generation sequencing (NGS), the latest powerful method for comprehensive genomic analysis, has recently revealed many kinds of chromosomal translocations in various TRSs. We often use experimental results to create custom probes for FISH and have applied NOCA2 split probes and CIC split, CIC-FOXO4 fusion probes to the pathological diagnosis of soft tissue angiofibroma and CIC-rearranged sarcoma, respectively. Some chimeric fusions detected by NGS induce the expression of related proteins and their detection using immunohistochemistry is beneficial for pathological diagnosis. We previously identified characteristic FOSB expression in pseudomyogenic hemangioendothelioma (PHE) with a specific SERPINE1-FOSB fusion, revealing the usefulness of FOSB immunohistochemistry in the differential diagnosis of PHE and its mimics. Finally, we participated in a central review of a clinical trial of trabectedin monotherapy. We guaranteed an accurate diagnosis by using FISH and genetic confirmation to select appropriate TRS patients and thereby confirm the accuracy of the patient enrollment of the clinical trial. FISH is an essential tool for the pathological diagnosis of soft tissue and bone tumors. It can detect various genetic abnormalities in an "in situ" fashion using FFPE specimens on glass slides during routine examination. It is also an excellent tool for translating the latest experimental findings to practical use in routine pathological diagnosis. Further instrumental improvements in FISH will help it to become the universal method for the genetic analysis of pathological diagnoses.
Copyright © 2017 The Japanese Orthopaedic Association. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28274512     DOI: 10.1016/j.jos.2017.02.004

Source DB:  PubMed          Journal:  J Orthop Sci        ISSN: 0949-2658            Impact factor:   1.601


  10 in total

Review 1.  Cellular and genomic approaches for exploring structural chromosomal rearrangements.

Authors:  Qing Hu; Elizabeth G Maurais; Peter Ly
Journal:  Chromosome Res       Date:  2020-01-13       Impact factor: 5.239

2.  Molecular Approaches to Diagnosis in Ewing Sarcoma: RT-PCR.

Authors:  Carlos Rodríguez-Martín; Javier Alonso
Journal:  Methods Mol Biol       Date:  2021

3.  Optimized workflow for digitalized FISH analysis in pathology.

Authors:  Vira Chea; Valerie Pleiner; Viviane Schweizer; Benjamin Herzog; Beata Bode; Marianne Tinguely
Journal:  Diagn Pathol       Date:  2021-05-11       Impact factor: 2.644

Review 4.  Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors.

Authors:  Natalia Magdalena Chrzanowska; Janusz Kowalewski; Marzena Anna Lewandowska
Journal:  Molecules       Date:  2020-04-17       Impact factor: 4.411

5.  Sex Chromosomes Are Severely Disrupted in Gastric Cancer Cell Lines.

Authors:  Sooeun Oh; Kyoungmi Min; Myungshin Kim; Suk Kyeong Lee
Journal:  Int J Mol Sci       Date:  2020-06-28       Impact factor: 5.923

6.  In situ hybridization to detect DNA amplification in extracellular vesicles.

Authors:  Lucia Casadei; Patricia Sarchet; Fernanda Costas C de Faria; Federica Calore; Giovanni Nigita; Sayumi Tahara; Luciano Cascione; Martin Wabitsch; Francis J Hornicek; Valerie Grignol; Carlo M Croce; Raphael E Pollock
Journal:  J Extracell Vesicles       Date:  2022-09

7.  Molecular classification of soft tissue sarcomas for adequate diagnosis: A study on the northeast population of Morocco.

Authors:  Rhizlane El Koubaiti; Asmae Mazti; Mustapha Maaroufi; Mohammed El Idrissi; Abdelhalim El Ibrahimi; Abdelmajid El Mrini; Touria Bouhafa; Samira El Fakir; Karim Ouldim; Samia Arifi; Laila Chbani
Journal:  Heliyon       Date:  2022-09-17

Review 8.  A Next-Generation Sequencing Primer-How Does It Work and What Can It Do?

Authors:  Yuriy O Alekseyev; Roghayeh Fazeli; Shi Yang; Raveen Basran; Thomas Maher; Nancy S Miller; Daniel Remick
Journal:  Acad Pathol       Date:  2018-05-06

Review 9.  Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy.

Authors:  Sandra Tuyaerts; Frédéric Amant
Journal:  Vaccines (Basel)       Date:  2018-08-25

10.  Molecular profiling of soft-tissue sarcomas with FoundationOne® Heme identifies potential targets for sarcoma therapy: a single-centre experience.

Authors:  Susanne Scheipl; Iva Brcic; Tina Moser; Stefan Fischerauer; Jakob Riedl; Marko Bergovec; Maria Smolle; Florian Posch; Armin Gerger; Martin Pichler; Herbert Stoeger; Andreas Leithner; Ellen Heitzer; Bernadette Liegl-Atzwanger; Joanna Szkandera
Journal:  Ther Adv Med Oncol       Date:  2021-07-25       Impact factor: 8.168

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.